We have a wide range of customers within the Wood Centre for Innovation.
Each company is part of our innovative community, with access to business support, flexible workspace and networking opportunities.
The Oxford Centre for Innovation is our sister site which hosts an equally diverse selection of companies.
Databasix works with companies to help them improve the way that data is collected, understood and used within the organisation.
DJS Antibodies is developing the next generation of therapeutics to treat the world’s most critical inflammatory diseases using HEPTAD, their revolutionary platform for antibody discovery. They are now owned by AbbVie.
The first joint Oxford and Cambridge university spinout, Helio uses innovations based on the outstanding properties of metal halide perovskites to create materials for a new generation of brighter, more colourful displays that use significantly less power.
Innovation Gateway enables organisations, like NatWest, Heathrow and Green King, to accelerate their progress to achieve their climate goals through actionable programmes and innovative technologies.
The only mail-in sperm testing company in the UK, Jack Fertility aims to change the conversation about fertility and address a gender imbalance in the lack of fertility testing and support available to men. Their at-home, mail-in sperm test kit gives men a new way to help navigate a challenging experience and, in doing so, give couples a more balanced approach to their fertility journeys. They are selling direct to consumers and then business to business in the UK with a European expansion on the horizon.
Lumai is focused on the development of groundbreaking all-optical neural networks. With the ever-increasing computational demands of AI, optical computing offers orders of magnitude improvements in performance and power efficiency. Lumai, spun out of the experimental optics research group of Professor Alex Lvovsky at the University of Oxford, has the vision of developing end-to-end all-optical neural networks where the information flow and calculations are minimally reliant on electronic processing.
Lurtis Rules designs, develops and implements AI technology for businesses in the fields of engineering, construction, health and finance to help them become more efficient, creative and innovative. Projects include developing intelligent tools to find new approaches for designing and configuring spaces and health applications to prevent dementia.
Marks & Clerk is one of the world’s leading intellectual property firms. Its team of patent attorneys, trade mark attorneys, and lawyers provides a full-service IP offering, from the initial filing of patents and registration of trade marks, through to litigation and commercial exploitation. The firm’s client base is diverse, ranging from new ventures to well known multinational corporations.
Oxford Hospitals Charity aims to transform care by funding the best medical equipment, research, training and facilities for patients and staff in local Oxfordshire hospitals.
PicturaBio is commercialising its innovative imaging technology to rapidly detect pathogens by using super-resolution microscopy and machine learning. Their technology comes from six years of research in the University of Oxford’s Department of Physics.
A biotech consultancy, Prismea helps streamline biodata analytics, creates cloud-based infrastructure, and develops InfoSec policies and processes tailored for individual businesses.
ProspectSoft is an innovative UK-based SaaS CRM and eCommerce company, which provides sales and marketing software to help B2B wholesalers, distributors and manufacturers drive growth.
Quorbit has developed strategic workforce planning software to enable large, complex organisations to build accurate labour demand forecasts driving improved labour budgeting and recruitment planning.
RedShiftBio provides next generation platform technology enabling measurements of previously undetectable structure changes in biomolecules through a powerful new analytic technique, Microfluidic Modulation Spectroscopy.
Samsara Therapeutics is developing new therapeutics that can boost autophagy to treat currently incurable neurodegenerative and rare genetic diseases, such as Parkinson’s, Huntington’s and ALS.
Network with like-minded innovators
Work among our many inspiring companies at the forefront of business.